- Home
- LXRX vs JANX Comparison
LXRX vs JANX Comparison
Compare LXRX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | JANX |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.3M | 840.4M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LXRX | JANX |
|---|---|---|
| Price | $2.49 | $14.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 13 |
| Target Price | $4.15 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,803,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $0.80 | $12.12 |
| 52 Week High | $2.53 | $35.34 |
Technical Indicators
Market Signals| Indicator | LXRX | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 74.41 | 55.15 |
| Support Level | $1.11 | $13.13 |
| Resistance Level | $2.53 | $15.49 |
| Average True Range (ATR) | 0.13 | 0.64 |
| MACD | 0.05 | 0.12 |
| Stochastic Oscillator | 97.10 | 61.30 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.